Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol Myers Squibb (NYSE: BMY) is scheduled to report its Q3 2022 results on Wednesday, October 26.

How Will Bristol Myers Squibb Stock Trend Post Q3 Results?

Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Should You Buy?

Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma

Cigna

STERIS

Sometimes, the strongest payout growth can be found among the future Dividend Aristocrats, not the current ones.

3 Fast-Growing Medical Dividend Stocks

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again

Chevron

These two stocks have solid fundamentals and are delivering strong results.

Got $5,000? These 2 Stocks Could Continue Beating the Bear Market.

ConocoPhillips

Exxon Mobil

Are these the best dividend stocks to invest in right now?

3 Top Dividend Stocks To Watch Today

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022

Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022

Axsome Therapeutics

Vertex Pharmaceuticals

These high-flying stocks are defying the bear market.

3 Stocks Savvy Investors Are Buying Hand Over Fist

The S&P 500 ETF (NYSEARCA: SPY ) has not performed well in 2022. It is down 22.4% so far this year, including dividends.

Best Stocks 2022: Why Bristol-Myers Squibb (BMY) Stock Is a Clear Winner

Exelixis

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced the expansion of its June 2021 Clinical Trial Collaboration and Supply Agreement with Bristol-Myers Squibb Company (NYSE: BMY) to include the use of the fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial (NCT05176483), which is evaluating XL092 in combination with multiple immune checkpoint inhibitors (ICIs) in advanced solid tumors. Exelixis is sponsoring STELLAR-0

Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial

BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.

Should Investors Buy Bristol Myers Squibb Stock?

Bristol Myers (BMY) expects recent drug approvals to generate an incremental stream of revenues and combat competition for its key drugs.

Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure?

Barrick Gold

Releasing two top October stocks from the long-term Growth and Dividend Breakout portfolio and ten top samples from prior portfolios. The October 2021 portfolio for 1 year is down -4.01% and the October 2020 2-year portfolio is up +3.65% not including additional minimum 2%+ dividends.

V&M Breakouts: Top Long-Term Growth And Dividend Stocks For October 2022

AbbVie

All three of these stocks are attractively valued even though they're beating the market this year.

Bear Market Bargains: 3 Dividend Stocks to Buy Now

The company's medicines received more than ten regulatory approvals in Europe, Japan, and the United States in the first half of 2022. Despite rising global inflation, Bristol-Myers Squibb's EBITDA was $5,363 million in Q2 2022, up 0.8% year-over-year.

Bristol-Myers Squibb: A Gem In A Period Of Macroeconomic Uncertainties

Abbott Labs

Acadia Healthcare

AstraZeneca

Cardinal Health

CVS Health

Johnson & Johnson

Merck

Novavax

Novartis

Pfizer

Regeneron Pharmaceuticals

Teladoc

UnitedHealth Group

Health care stocks are traditionally a defensive play for investors in a falling market. It's a rich market with blue chip insurance providers, service providers, pharmaceutical companies, retailers, and tech players.

Health Care Stocks: Reviewing The Best Of The Industry

These businesses might be slightly "boring," but that may just be a good thing in today's market.

Bear Market: 2 Safe Stocks to Buy Right Now

Ventyx Biosciences

Big Pharma Bristol Myers Squibb won approval for plaque psoriasis therapy Sotyktu on September 9th - the drug may have $4bn peak sales potential. Ventyx has a drug with the same MoA entering a Phase 2 study. Phase 1 data suggests it could be superior to Sotyktu.

Bristol Myers Sotyktu Approval Sends Ventyx Stock Soaring: Consider Buying Both

The big pharma stock continues to trounce the major market indexes so far this year.

Why Bristol Myers Squibb Stock Bounced Higher Today

EDP Renewables Starts Construction on 240-Megawatt Texas Solar Park

Bristol Myers (BMY) gets EC approval for the fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor Opdivo (nivolumab and novel LAG-3-blocking antibody relatlimab.

Bristol Myers (BMY) Skin Cancer Drug Gets EC's Approval

Forbes is tracking the biggest layoffs in the U.S. this summer as companies react to fears of a looming recession.

Calif. Pharmaceutical Companies AbbVie And Bristol Myers Lay Off 360—Here Are The Major U.S. Layoffs This Summer

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

Drugmakers Bristol Myers Squibb Co and AbbVie Inc told California officials that they plan to cut up to 360 jobs there in unrelated moves, according to notices filed with the state that were made public earlier this week.

News for Bristol-Myers Stock (BMY)